{"id":"bisoprolol","rwe":[{"pmid":"41877729","year":"2026","title":"One- and two-year structural changes of mavacamten therapy in hypertrophic obstructive cardiomyopathy: a case report with serial comprehensive CMR demonstrating continuous reverse remodelling.","finding":"","journal":"European heart journal. Case reports","studyType":"Clinical Study"},{"pmid":"41810798","year":"2026","title":"Systemic medications associate with surgically treated cataract among adults over 50 years in Finland.","finding":"","journal":"Acta ophthalmologica","studyType":"Clinical Study"},{"pmid":"41809863","year":"2026","title":"Acute effects of low-dose bisoprolol on lung function and blood pressure in COPD patients.","finding":"","journal":"ERJ open research","studyType":"Clinical Study"},{"pmid":"41808274","year":"2026","title":"Unrepaired Truncus Arteriosus Type 1 With Eisenmenger Syndrome and Recurrent Embolic Strokes: An Adult Case Report.","finding":"","journal":"The American journal of case reports","studyType":"Clinical Study"},{"pmid":"41804409","year":"2026","title":"A Prospective Clinical Audit to Improve Compliance With Perioperative Atrial Fibrillation Prevention Protocols in Off-Pump Coronary Artery Bypass Surgery.","finding":"","journal":"Cureus","studyType":"Clinical Study"}],"_fda":{"id":"e8b6cea1-8a7f-4255-8a24-ff96d6ceece2","set_id":"084308e4-3b8b-40d6-acbf-d775772a8a73","openfda":{"upc":["0343547616038","0343547617035"],"unii":["UR59KN573L"],"route":["ORAL"],"rxcui":["854901","854905"],"spl_id":["e8b6cea1-8a7f-4255-8a24-ff96d6ceece2"],"brand_name":["Bisoprolol fumarate"],"spl_set_id":["084308e4-3b8b-40d6-acbf-d775772a8a73"],"package_ndc":["43547-616-03","43547-616-10","43547-616-50","43547-617-03","43547-617-10","43547-617-50"],"product_ndc":["43547-616","43547-617"],"generic_name":["BISOPROLOL FUMARATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["BISOPROLOL FUMARATE"],"manufacturer_name":["Solco Healthcare US, LLC"],"application_number":["ANDA217368"],"is_original_packager":[true]},"version":"3","warnings":["WARNINGS Click here to enter Warnings Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in the setting of congestive heart failure, and beta-blockade may result in further depression of myocardial contractility and precipitate more severe failure. In general, beta-blocking agents should be avoided in patients with overt congestive failure. However, in some patients with compensated cardiac failure it may be necessary to utilize them. In such a situation, they must be used cautiously. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blockers can, in some patients, precipitate cardiac failure. At the first signs or symptoms of heart failure, discontinuation of bisoprolol fumarate tablets should be considered. In some cases, beta-blocker therapy can be continued while heart failure is treated with other drugs. Abrupt Cessation of Therapy Exacerbation of angina pectoris, and, in some instances, myocardial infarction or ventricular arrhythmia, have been observed in patients with coronary artery disease following abrupt cessation of therapy with beta-blockers. Such patients should, therefore, be cautioned against interruption or discontinuation of therapy without the physician’s advice. Even in patients without overt coronary artery disease, it may be advisable to taper therapy with bisoprolol fumarate tablets over approximately one week with the patient under careful observation. If withdrawal symptoms occur, bisoprolol fumarate tablets therapy should be reinstituted, at least temporarily. Peripheral Vascular Disease Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. Caution should be exercised in such individuals. Bronchospastic Disease PATIENTS WITH BRONCHOSPASTIC DISEASE SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta 1 -selectivity, however, bisoprolol fumarate tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. Since beta 1 -selectivity is not absolute, the lowest possible dose of bisoprolol fumarate tablets should be used, with therapy starting at 2.5 mg. A beta 2 agonist (bronchodilator) should be made available. Major Surgery Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures. Diabetes and Hypoglycemia Beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia. Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. Because of its beta 1 -selectivity, this is less likely with bisoprolol fumarate tablets. However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. Thyrotoxicosis Beta-adrenergic blockade may mask clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm."],"pregnancy":["Pregnancy In rats, bisoprolol fumarate was not teratogenic at doses up to 150 mg/kg/day which is 375 and 77 times the MRHD on the basis of body weight and body surface area, respectively. Bisoprolol fumarate was fetotoxic (increased late resorptions) at 50 mg/kg/day and maternotoxic (decreased food intake and body weight gain) at 150 mg/kg/day. The fetotoxicity in rats occurred at 125 times the MRHD on a body weight basis and 26 times the MRHD on the basis of body surface area. The maternotoxicity occurred at 375 times the MRHD on a body weight basis and 77 times the MRHD on the basis of body surface area. In rabbits, bisoprolol fumarate was not teratogenic at doses up to 12.5 mg/kg/day, which is 31 and 12 times the MRHD based on body weight and body surface area, respectively, but was embryolethal (increased early resorptions) at 12.5 mg/kg/day. There are no adequate and well-controlled studies in pregnant women. Bisoprolol fumarate tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"overdosage":["OVERDOSAGE The most common signs expected with overdosage of a beta-blocker are bradycardia, hypotension, congestive heart failure, bronchospasm, and hypoglycemia. To date, a few cases of overdose (maximum: 2000 mg) with bisoprolol fumarate have been reported. Bradycardia and/or hypotension were noted. Sympathomimetic agents were given in some cases, and all patients recovered. In general, if overdose occurs, bisoprolol fumarate tablets therapy should be stopped and supportive and symptomatic treatment should be provided. Limited data suggest that bisoprolol fumarate is not dialyzable. Based on the expected pharmacologic actions and recommendations for other beta-blockers, the following general measures should be considered when clinically warranted: Bradycardia Administer IV atropine. If the response is inadequate, isoproterenol or another agent with positive chronotropic properties may be given cautiously. Under some circumstances, transvenous pacemaker insertion may be necessary. Hypotension IV fluids and vasopressors should be administered. Intravenous glucagon may be useful. Heart Block (second or third degree) Patients should be carefully monitored and treated with isoproterenol infusion or transvenous cardiac pacemaker insertion, as appropriate. Congestive Heart Failure Initiate conventional therapy (ie, digitalis, diuretics, inotropic agents, vasodilating agents). Bronchospasm Administer bronchodilator therapy such as isoproterenol and/or aminophylline. Hypoglycemia Administer IV glucose."],"description":["DESCRIPTION Bisoprolol fumarate tablets are a synthetic, beta 1 -selective (cardioselective) adrenoceptor blocking agent. The chemical name for bisoprolol fumarate is (±)-1-[4-[[2-(1-Methylethoxy)ethoxy]methyl]phenoxy]-3‑ [(1-methylethyl)amino]-2-propanol( E )-2-butenedioate (2:1) (salt). It possesses an asymmetric carbon atom in its structure and is provided as a racemic mixture. The S(-) enantiomer is responsible for most of the beta-blocking activity. Its empirical formula is (C 18 H 31 NO 4 ) 2 •C 4 H 4 O 4 and its structure is: Bisoprolol fumarate, USP, has a molecular weight of 766.97. It is a white crystalline powder which is approximately equally hydrophilic and lipophilic, and is readily soluble in water, methanol, ethanol, and chloroform. Bisoprolol fumarate tablets are available as 5 and 10 mg tablets for oral administration. Inactive ingredients include Colloidal Silicon Dioxide, Crospovidone, Dicalcium Phosphate Anhydrous, Magnesium Stearate, Mannitol, Microcrystalline Cellulose, Pregelatinized Starch. The coating materials for all strengths contain Macrogol/PEG, Polyvinyl Alcohol-part hydrolyzed, Talc, Titanium Dioxide. The 5 mg tablets also contain Red Iron Oxide. FDA approved dissolution test specifications differ from USP. structure"],"precautions":["PRECAUTIONS Impaired Renal or Hepatic Function Use caution in adjusting the dose of bisoprolol fumarate tablets in patients with renal or hepatic impairment (see CLINICAL PHARMACOLOGY ). Drug Interactions Bisoprolol fumarate tablets should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of bisoprolol fumarate tablets may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that bisoprolol fumarate tablets be discontinued for several days before the withdrawal of clonidine. Bisoprolol fumarate tablets should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate tablets, resulting in a shortened elimination half-life of bisoprolol fumarate tablets. However, initial dose modification is generally not necessary. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine. There was no effect of bisoprolol fumarate tablets on prothrombin time in patients on stable doses of warfarin. Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. Information for Patients Patients, especially those with coronary artery disease, should be warned about discontinuing use of bisoprolol fumarate tablets without a physician’s supervision. Patients should also be advised to consult a physician if any difficulty in breathing occurs, or if they develop signs or symptoms of congestive heart failure or excessive bradycardia. Patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned that beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia, and bisoprolol fumarate should be used with caution. Patients should know how they react to this medicine before they operate automobiles and machinery or engage in other tasks requiring alertness. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies were conducted with oral bisoprolol fumarate administered in the feed of mice (20 and 24 months) and rats (26 months). No evidence of carcinogenic potential was seen in mice dosed up to 250 mg/kg/day or rats dosed up to 125 mg/kg/day. On a body weight basis, these doses are 625 and 312 times, respectively, the maximum recommended human dose (MRHD) of 20 mg, (or 0.4 mg/kg/day based on a 50 kg individual); on a body surface area basis, these doses are 59 times (mice) and 64 times (rats) the MRHD. The mutagenic potential of bisoprolol fumarate was evaluated in the microbial mutagenicity (Ames) test, the point mutation and chromosome aberration assays in Chinese hamster V79 cells, the unscheduled DNA synthesis test, the micronucleus test in mice, and the cytogenetics assay in rats. There was no evidence of mutagenic potential in these in vitro and in vivo assays. Reproduction studies in rats did not show any impairment of fertility at doses up to 150 mg/kg/day of bisoprolol fumarate, or 375 and 77 times the MRHD on the basis of body weight and body surface area, respectively. Pregnancy In rats, bisoprolol fumarate was not teratogenic at doses up to 150 mg/kg/day which is 375 and 77 times the MRHD on the basis of body weight and body surface area, respectively. Bisoprolol fumarate was fetotoxic (increased late resorptions) at 50 mg/kg/day and maternotoxic (decreased food intake and body weight gain) at 150 mg/kg/day. The fetotoxicity in rats occurred at 125 times the MRHD on a body weight basis and 26 times the MRHD on the basis of body surface area. The maternotoxicity occurred at 375 times the MRHD on a body weight basis and 77 times the MRHD on the basis of body surface area. In rabbits, bisoprolol fumarate was not teratogenic at doses up to 12.5 mg/kg/day, which is 31 and 12 times the MRHD based on body weight and body surface area, respectively, but was embryolethal (increased early resorptions) at 12.5 mg/kg/day. There are no adequate and well-controlled studies in pregnant women. Bisoprolol fumarate tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Small amounts of bisoprolol fumarate (< 2% of the dose) have been detected in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when bisoprolol fumarate is administered to nursing women. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Bisoprolol fumarate tablets have been used in elderly patients with hypertension. Response rates and mean decreases in systolic and diastolic blood pressure were similar to the decreases in younger patients in the U.S. clinical studies. Although no dose response study was conducted in elderly patients, there was a tendency for older patients to be maintained on higher doses of bisoprolol fumarate. Observed reductions in heart rate were slightly greater in the elderly than in the young and tended to increase with increasing dose. In general, no disparity in adverse experience reports or dropouts for safety reasons was observed between older and younger patients. Dose adjustment based on age is not necessary."],"how_supplied":["HOW SUPPLIED Bisoprolol fumarate tablets, USP, are supplied as 5 mg and 10 mg tablets. The 5 mg tablet is pink color coated tablet, capsule shaped, convex scored tablets debossed with “6|6” on one side and “S” on the other side, supplied as follows: bottles of 30 (Unit-of-Use) NDC 43547-616-03 bottles of 100 NDC 43547-616-10 bottles of 500 NDC 43547-616-50 The 10 mg tablet is white color coated tablet, round shaped, convex tablets debossed with “6 7” on one side and “S” on the other side, supplied as follows: bottles of 30 (Unit-of-Use) NDC 43547-617-03 bottles of 100 NDC 43547-617-10 bottles of 500 NDC 43547-617-50 Store at 20 o C to 25 o C (68 o Fto 77 o F); excursions permitted to 15 o C to 30 o C (59 o Fto 86 o F) [see USP Controlled Room Temperature]. Protect from moisture. Dispense in tight, light resistant containers. Distributed by: Solco Healthcare US, LLC Somerset, NJ 08873, USA Manufactured by: Prinston Laboratories Charlotte, NC 28206, USA Revised: 06/2023 9040560-01"],"geriatric_use":["Geriatric Use Bisoprolol fumarate tablets have been used in elderly patients with hypertension. Response rates and mean decreases in systolic and diastolic blood pressure were similar to the decreases in younger patients in the U.S. clinical studies. Although no dose response study was conducted in elderly patients, there was a tendency for older patients to be maintained on higher doses of bisoprolol fumarate. Observed reductions in heart rate were slightly greater in the elderly than in the young and tended to increase with increasing dose. In general, no disparity in adverse experience reports or dropouts for safety reasons was observed between older and younger patients. Dose adjustment based on age is not necessary."],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20230626","nursing_mothers":["Nursing Mothers Small amounts of bisoprolol fumarate (< 2% of the dose) have been detected in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when bisoprolol fumarate is administered to nursing women."],"clinical_studies":["CLINICAL STUDIES In two randomized double-blind placebo-controlled trials conducted in the U.S., reductions in systolic and diastolic blood pressure and heart rate 24 hours after dosing in patients with mild-to-moderate hypertension are shown below. In both studies, mean systolic/diastolic blood pressures at baseline were approximately 150/100 mm Hg, and mean heart rate was 76 bpm. Drug effect is calculated by subtracting the placebo effect from the overall change in blood pressure and heart rate. Sitting Systolic/Diastolic Pressure (BP) and Heart Rate (HR) Mean Decrease (D) After 3 to 4 Weeks Study A Bisoprolol Fumarate Placebo 5 mg 10 mg 20 mg n= 61 61 61 61 Total ΔBP (mm Hg) 5.4/3.2 10.4/8.0 11.2/10.9 12.8/11.9 Drug Effect a - 5.0/4.8 5.8/7.7 7.4/8.7 Total ΔHR (bpm) 0.5 7.2 8.7 11.3 Drug Effect a - 6.7 8.2 10.8 Study B Bisoprolol Fumarate Placebo 2.5 mg 10 mg n= 56 59 62 Total ΔBP (mm Hg) 3.0/3.7 7.6/8.1 13.5/11.2 Drug Effect a - 4.6/4.4 10.5/7.5 Total ΔHR (bpm) 1.6 3.8 10.7 Drug Effect a - 2.2 9.1 a Observed total change from baseline minus placebo. Blood pressure responses were seen within one week of treatment and changed little thereafter. They were sustained for 12 weeks and for over a year in studies of longer duration. Blood pressure returned to baseline when bisoprolol fumarate was tapered over two weeks in a long-term study. Overall, significantly greater blood pressure reductions were observed on bisoprolol fumarate than on placebo regardless of race, age, or gender. There were no significant differences in response between black and nonblack patients."],"adverse_reactions":["ADVERSE REACTIONS Safety data are available in more than 30,000 patients or volunteers. Frequency estimates and rates of withdrawal of therapy for adverse events were derived from two U.S. placebo-controlled studies. In Study A, doses of 5, 10, and 20 mg bisoprolol fumarate were administered for 4 weeks. In Study B, doses of 2.5, 10, and 40 mg of bisoprolol fumarate were administered for 12 weeks. A total of 273 patients were treated with 5-20 mg of bisoprolol fumarate; 132 received placebo. Withdrawal of therapy for adverse events was 3.3% for patients receiving bisoprolol fumarate and 6.8% for patients on placebo. Withdrawals were less than 1% for either bradycardia or fatigue/lack of energy. The following table presents adverse experiences, whether or not considered drug related, reported in at least 1% of patients in these studies, for all patients studied in placebo-controlled clinical trials (2.5-40 mg), as well as for a subgroup that was treated with doses within the recommended dosage range (5-20 mg). Of the adverse events listed in the table, bradycardia, diarrhea, asthenia, fatigue, and sinusitis appear to be dose related. Body System/Adverse Experience All Adverse Experiences (% a ) Bisoprolol Fumarate Placebo (n=132) % 5-20 mg (n=273) % 2.5-40 mg (n=404) % Skin increased sweating 1.5 0.7 1.0 Musculoskeletal arthralgia 2.3 2.2 2.7 Central Nervous System dizziness 3.8 2.9 3.5 headache 11.4 8.8 10.9 hypoaesthesia 0.8 1.1 1.5 Autonomic Nervous System dry mouth 1.5 0.7 1.3 Heart Rate/Rhythm bradycardia 0 0.4 0.5 Psychiatric vivid dreams 0 0 0 insomnia 2.3 1.5 2.5 depression 0.8 0 0.2 Gastrointestinal diarrhea 1.5 2.6 3.5 nausea 1.5 1.5 2.2 vomiting 0 1.1 1.5 Respiratory bronchospasm 0 0 0 cough 4.5 2.6 2.5 dyspnea 0.8 1.1 1.5 pharyngitis 2.3 2.2 2.2 rhinitis 3.0 2.9 4.0 sinusitis 1.5 2.2 2.2 URI 3.8 4.8 5.0 Body as a Whole asthenia 0 0.4 1.5 chest pain 0.8 1.1 1.5 fatigue 1.5 6.6 8.2 edema (peripheral) 3.8 3.7 3.0 a percentage of patients with event The following is a comprehensive list of adverse experiences reported with bisoprolol fumarate in worldwide studies, or in postmarketing experience (in italics): Central Nervous System Dizziness, unsteadiness, vertigo, syncope, headache, paresthesia, hypoesthesia, hyperesthesia, somnolence, sleep disturbances, anxiety/restlessness, decreased concentration/memory. Autonomic Nervous System Dry mouth. Cardiovascular Bradycardia, palpitations and other rhythm disturbances, cold extremities, claudication, hypotension, orthostatic hypotension, chest pain, congestive heart failure, dyspnea on exertion. Psychiatric Vivid dreams, insomnia, depression. Gastrointestinal Gastric/epigastric/abdominal pain, gastritis, dyspepsia, nausea, vomiting, diarrhea, constipation, peptic ulcer. Musculoskeletal Muscle/joint pain, arthralgia , back/neck pain, muscle cramps, twitching/tremor. Skin Rash, acne, eczema, psoriasis , skin irritation, pruritus, flushing, sweating, alopecia, dermatitis, angioedema, exfoliative dermatitis , cutaneous vasculitis. Special Senses Visual disturbances, ocular pain/pressure, abnormal lacrimation, tinnitus, decreased hearing , earache, taste abnormalities. Metabolic Gout. Respiratory Asthma/bronchospasm, bronchitis, coughing, dyspnea, pharyngitis, rhinitis, sinusitis, URI. Genitourinary Decreased libido/impotence, Peyronie’s disease , cystitis, renal colic, polyuria. Hematologic Purpura. General Fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema. In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects of bisoprolol fumarate tablets: Central Nervous System Reversible mental depression progressing to catatonia, hallucinations, an acute reversible syndrome characterized by disorientation to time and place, emotional lability, slightly clouded sensorium. Allergic Fever, combined with aching and sore throat, laryngospasm, respiratory distress. Hematologic Agranulocytosis, thrombocytopenia, thrombocytopenic purpura. Gastrointestinal Mesenteric arterial thrombosis, ischemic colitis. Miscellaneous The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with bisoprolol fumarate tablets during investigational use or extensive foreign marketing experience."],"contraindications":["CONTRAINDICATIONS Bisoprolol fumarate tablets are contraindicated in patients with cardiogenic shock, overt cardiac failure, second or third degree AV block, and marked sinus bradycardia."],"general_precautions":["Impaired Renal or Hepatic Function Use caution in adjusting the dose of bisoprolol fumarate tablets in patients with renal or hepatic impairment (see CLINICAL PHARMACOLOGY )."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Bisoprolol fumarate tablets are a beta 1 -selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range. Cardioselectivity is not absolute, however, and at higher doses (≥ 20 mg) bisoprolol fumarate also inhibits beta 2 -adrenoceptors, chiefly located in the bronchial and vascular musculature; to retain selectivity it is therefore important to use the lowest effective dose. Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%. Absorption is not affected by the presence of food. The first pass metabolism of bisoprolol fumarate is about 20%. Binding to serum proteins is approximately 30%. Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg. Once daily dosing with bisoprolol fumarate results in less than twofold intersubject variation in peak plasma levels. The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population. Steady state is attained within 5 days of once daily dosing. In both young and elderly populations, plasma accumulation is low; the accumulation factor ranges from 1.1 to 1.3, and is what would be expected from the first order kinetics and once daily dosing. Plasma concentrations are proportional to the administered dose in the range of 5 to 20 mg. Pharmacokinetic characteristics of the two enantiomers are similar. Bisoprolol fumarate is eliminated equally by renal and non-renal pathways with about 50% of the dose appearing unchanged in the urine and the remainder appearing in the form of inactive metabolites. In humans, the known metabolites are labile or have no known pharmacologic activity. Less than 2% of the dose is excreted in the feces. Bisoprolol fumarate is not metabolized by cytochrome P450 II D6 (debrisoquin hydroxylase). In subjects with creatinine clearance less than 40 mL/min, the plasma half-life is increased approximately threefold compared to healthy subjects. In patients with cirrhosis of the liver, the elimination of bisoprolol fumarate tablets is more variable in rate and significantly slower than that in healthy subjects, with plasma half-life ranging from 8.3 to 21.7 hours. Pharmacodynamics The most prominent effect of bisoprolol fumarate tablets is the negative chronotropic effect, resulting in a reduction in resting and exercise heart rate. There is a fall in resting and exercise cardiac output with little observed change in stroke volume, and only a small increase in right atrial pressure, or pulmonary capillary wedge pressure at rest or during exercise. Findings in short-term clinical hemodynamics studies with bisoprolol fumarate tablets are similar to those observed with other beta-blocking agents. The mechanism of action of its antihypertensive effects has not been completely established. Factors which may be involved include: 1) Decreased cardiac output, 2) Inhibition of renin release by the kidneys, 3) Diminution of tonic sympathetic outflow from the vasomotor centers in the brain. In normal volunteers, bisoprolol fumarate tablets therapy resulted in a reduction of exercise- and isoproterenol-induced tachycardia. The maximal effect occurred within 1-4 hours post-dosing. Effects persisted for 24 hours at doses equal to or greater than 5 mg. Electrophysiology studies in man have demonstrated that bisoprolol fumarate tablets significantly decreases heart rate, increases sinus node recovery time, prolongs AV node refractory periods, and, with rapid atrial stimulation, prolongs AV nodal conduction. Beta 1 -selectivity of bisoprolol fumarate tablets has been demonstrated in both animal and human studies. No effects at therapeutic doses on beta 2 -adrenoceptor density have been observed. Pulmonary function studies have been conducted in healthy volunteers, asthmatics, and patients with chronic obstructive pulmonary disease (COPD). Doses of bisoprolol fumarate tablets ranged from 5 to 60 mg, atenolol from 50 to 200 mg, metoprolol from 100 to 200 mg, and propranolol from 40 to 80 mg. In some studies, slight, asymptomatic increases in airways resistance (AWR) and decreases in forced expiratory volume (FEV 1 ) were observed with doses of bisoprolol fumarate 20 mg and higher, similar to the small increases in AWR also noted with the other cardioselective beta-blockers. The changes induced by beta- blockade with all agents were reversed by bronchodilator therapy. Bisoprolol fumarate tablets had minimal effect on serum lipids during antihypertensive studies. In U.S. placebo-controlled trials, changes in total cholesterol averaged +0.8% for bisoprolol fumarate-treated patients, and +0.7% for placebo. Changes in triglycerides averaged +19% for bisoprolol fumarate-treated patients, and +17% for placebo. Bisoprolol fumarate tablets have also been given concomitantly with thiazide diuretics. Even very low doses of hydrochlorothiazide (6.25 mg) were found to be additive with bisoprolol fumarate in lowering blood pressure in patients with mild-to-moderate hypertension."],"indications_and_usage":["INDICATIONS AND USAGE Bisoprolol fumarate tablets are indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents."],"clinical_studies_table":["<table width=\"100%\"><col width=\"21%\"/><col width=\"14%\"/><col width=\"18%\"/><col width=\"23%\"/><col width=\"21%\"/><tbody><tr><td align=\"center\" colspan=\"5\" valign=\"top\"><paragraph><content styleCode=\"bold\">Sitting Systolic/Diastolic Pressure (BP) and Heart Rate (HR)</content></paragraph><paragraph><content styleCode=\"bold\">Mean Decrease (D) After 3 to 4 Weeks</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">Study A</content></content></paragraph></td><td valign=\"top\"/><td colspan=\"2\" valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">Bisoprolol Fumarate</content></content></paragraph></td><td valign=\"top\"/></tr><tr><td valign=\"top\"/><td valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">Placebo</content></content></paragraph></td><td valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">5 mg</content></content></paragraph></td><td valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">10 mg</content></content></paragraph></td><td valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">20 mg</content></content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>n=</paragraph></td><td valign=\"top\"><paragraph>61</paragraph></td><td valign=\"top\"><paragraph>61</paragraph></td><td valign=\"top\"><paragraph>61</paragraph></td><td valign=\"top\"><paragraph>61</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Total &#x394;BP (mm Hg)</paragraph></td><td valign=\"top\"><paragraph>5.4/3.2</paragraph></td><td valign=\"top\"><paragraph>10.4/8.0</paragraph></td><td valign=\"top\"><paragraph>11.2/10.9</paragraph></td><td valign=\"top\"><paragraph>12.8/11.9</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Drug Effect<sup>a</sup></paragraph></td><td valign=\"top\"><paragraph>-</paragraph></td><td valign=\"top\"><paragraph>5.0/4.8</paragraph></td><td valign=\"top\"><paragraph>5.8/7.7</paragraph></td><td valign=\"top\"><paragraph>7.4/8.7</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Total &#x394;HR (bpm)</paragraph></td><td valign=\"top\"><paragraph>0.5</paragraph></td><td valign=\"top\"><paragraph>7.2</paragraph></td><td valign=\"top\"><paragraph>8.7</paragraph></td><td valign=\"top\"><paragraph>11.3</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Drug Effect<sup>a</sup></paragraph></td><td valign=\"top\"><paragraph>-</paragraph></td><td valign=\"top\"><paragraph>6.7</paragraph></td><td valign=\"top\"><paragraph>8.2</paragraph></td><td valign=\"top\"><paragraph>10.8</paragraph></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">Study B</content></content></paragraph></td><td valign=\"top\"/><td colspan=\"2\" valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">Bisoprolol Fumarate</content></content></paragraph></td><td valign=\"top\"/></tr><tr><td valign=\"top\"/><td valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">Placebo</content></content></paragraph></td><td valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">2.5 mg</content></content></paragraph></td><td valign=\"top\"><paragraph><content styleCode=\"bold\"><content styleCode=\"underline\">10 mg</content></content></paragraph></td><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph>n=</paragraph></td><td valign=\"top\"><paragraph>56</paragraph></td><td valign=\"top\"><paragraph>59</paragraph></td><td valign=\"top\"><paragraph>62</paragraph></td><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph>Total &#x394;BP (mm Hg)</paragraph></td><td valign=\"top\"><paragraph>3.0/3.7</paragraph></td><td valign=\"top\"><paragraph>7.6/8.1</paragraph></td><td valign=\"top\"><paragraph>13.5/11.2</paragraph></td><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph>Drug Effect<sup>a</sup></paragraph></td><td valign=\"top\"><paragraph>-</paragraph></td><td valign=\"top\"><paragraph>4.6/4.4</paragraph></td><td valign=\"top\"><paragraph>10.5/7.5</paragraph></td><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph>Total &#x394;HR (bpm)</paragraph></td><td valign=\"top\"><paragraph>1.6</paragraph></td><td valign=\"top\"><paragraph>3.8</paragraph></td><td valign=\"top\"><paragraph>10.7</paragraph></td><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph>Drug Effect<sup>a</sup></paragraph></td><td valign=\"top\"><paragraph>-</paragraph></td><td valign=\"top\"><paragraph>2.2</paragraph></td><td valign=\"top\"><paragraph>9.1</paragraph></td><td valign=\"top\"/></tr><tr><td colspan=\"4\" styleCode=\"Botrule \" valign=\"top\"><paragraph><sup>a </sup>Observed total change from baseline minus placebo.</paragraph></td><td styleCode=\"Botrule \" valign=\"top\"/></tr></tbody></table>"],"adverse_reactions_table":["<table width=\"100%\"><col width=\"32%\"/><col width=\"17%\"/><col width=\"25%\"/><col width=\"25%\"/><thead><tr><th align=\"left\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\"><content styleCode=\"underline\">Body System/Adverse Experience</content></content></th><th align=\"center\" colspan=\"3\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\"><content styleCode=\"underline\">All Adverse Experiences (%<sup>a</sup>)</content></content> <content styleCode=\"bold\"><content styleCode=\"underline\">Bisoprolol Fumarate</content></content></th></tr><tr><th align=\"left\" styleCode=\"Botrule \" valign=\"top\"/><th align=\"center\" styleCode=\"Botrule \" valign=\"top\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n=132)</content> <content styleCode=\"bold\"><content styleCode=\"underline\">%</content></content></th><th align=\"center\" styleCode=\"Botrule \" valign=\"top\"><content styleCode=\"bold\">5-20 mg</content> <content styleCode=\"bold\">(n=273)</content> <content styleCode=\"bold\"><content styleCode=\"underline\">%</content></content></th><th align=\"center\" styleCode=\"Botrule \" valign=\"top\"><content styleCode=\"bold\">2.5-40 mg</content> <content styleCode=\"bold\">(n=404)</content> <content styleCode=\"bold\"><content styleCode=\"underline\">%</content></content></th></tr></thead><tbody><tr><td styleCode=\"Toprule \" valign=\"top\"><paragraph>Skin</paragraph></td><td styleCode=\"Toprule \" valign=\"top\"/><td styleCode=\"Toprule \" valign=\"top\"/><td styleCode=\"Toprule \" valign=\"top\"/></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>increased sweating</item></list></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.0</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Musculoskeletal</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>arthralgia</item></list></td><td align=\"center\" valign=\"top\"><paragraph>2.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.7</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Central Nervous System</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>dizziness</item></list></td><td align=\"center\" valign=\"top\"><paragraph>3.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>3.5</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>headache</item></list></td><td align=\"center\" valign=\"top\"><paragraph>11.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>8.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>10.9</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>hypoaesthesia</item></list></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Autonomic Nervous System</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>dry mouth</item></list></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.3</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Heart Rate/Rhythm</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>bradycardia</item></list></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.5</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Psychiatric</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>vivid dreams</item></list></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>insomnia</item></list></td><td align=\"center\" valign=\"top\"><paragraph>2.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.5</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>depression</item></list></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.2</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Gastrointestinal</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>diarrhea</item></list></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>3.5</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>nausea</item></list></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>vomiting</item></list></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Respiratory</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>bronchospasm</item></list></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>cough</item></list></td><td align=\"center\" valign=\"top\"><paragraph>4.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.5</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>dyspnea</item></list></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>pharyngitis</item></list></td><td align=\"center\" valign=\"top\"><paragraph>2.3</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>rhinitis</item></list></td><td align=\"center\" valign=\"top\"><paragraph>3.0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.9</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4.0</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>sinusitis</item></list></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2.2</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>URI</item></list></td><td align=\"center\" valign=\"top\"><paragraph>3.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5.0</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Body as a Whole</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>asthenia</item></list></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>chest pain</item></list></td><td align=\"center\" valign=\"top\"><paragraph>0.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>fatigue</item></list></td><td align=\"center\" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>6.6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>8.2</paragraph></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption> </caption>edema (peripheral)</item></list></td><td align=\"center\" valign=\"top\"><paragraph>3.8</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>3.7</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>3.0</paragraph></td></tr><tr><td colspan=\"4\" styleCode=\"Botrule \" valign=\"top\"><paragraph><sup>a </sup>percentage of patients with event</paragraph></td></tr></tbody></table>"],"information_for_patients":["Information for Patients Patients, especially those with coronary artery disease, should be warned about discontinuing use of bisoprolol fumarate tablets without a physician’s supervision. Patients should also be advised to consult a physician if any difficulty in breathing occurs, or if they develop signs or symptoms of congestive heart failure or excessive bradycardia. Patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned that beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia, and bisoprolol fumarate should be used with caution. Patients should know how they react to this medicine before they operate automobiles and machinery or engage in other tasks requiring alertness."],"spl_unclassified_section":["LABORATORY ABNORMALITIES In clinical trials, the most frequently reported laboratory change was an increase in serum triglycerides, but this was not a consistent finding. Sporadic liver test abnormalities have been reported. In the U.S. controlled trials experience with bisoprolol fumarate treatment for 4-12 weeks, the incidence of concomitant elevations in SGOT and SGPT from 1 to 2 times normal was 3.9%, compared to 2.5% for placebo. No patient had concomitant elevations greater than twice normal. In the long-term, uncontrolled experience with bisoprolol fumarate treatment for 6-18 months, the incidence of one or more concomitant elevations in SGOT and SGPT from 1 to 2 times normal was 6.2%. The incidence of multiple occurrences was 1.9%. For concomitant elevations in SGOT and SGPT of greater than twice normal, the incidence was 1.5%. The incidence of multiple occurrences was 0.3%. In many cases these elevations were attributed to underlying disorders, or resolved during continued treatment with bisoprolol fumarate. Other laboratory changes included small increases in uric acid, creatinine, BUN, serum potassium, glucose, and phosphorus and decreases in WBC and platelets. These were generally not of clinical importance and rarely resulted in discontinuation of bisoprolol fumarate. As with other beta-blockers, ANA conversions have also been reported on bisoprolol fumarate. About 15% of patients in long-term studies converted to a positive titer, although about one-third of these patients subsequently reconverted to a negative titer while on continued therapy."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The dose of bisoprolol fumarate tablets must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose (see Bronchospastic Disease in WARNINGS ). If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily. Patients with Renal or Hepatic Impairment In patients with hepatic impairment (hepatitis or cirrhosis) or renal dysfunction (creatinine clearance less than 40 mL/min), the initial daily dose should be 2.5 mg and caution should be used in dose-titration. Since limited data suggest that bisoprolol fumarate is not dialyzable, drug replacement is not necessary in patients undergoing dialysis. Geriatric Patients It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and Geriatric Use in PRECAUTIONS ). Pediatric Patients There is no pediatric experience with bisoprolol fumarate tablets."],"spl_product_data_elements":["Bisoprolol fumarate Bisoprolol fumarate BISOPROLOL FUMARATE BISOPROLOL CROSPOVIDONE, UNSPECIFIED DIBASIC CALCIUM PHOSPHATE DIHYDRATE FERRIC OXIDE RED MAGNESIUM STEARATE MANNITOL MICROCRYSTALLINE CELLULOSE POLYETHYLENE GLYCOL, UNSPECIFIED POLYVINYL ALCOHOL, UNSPECIFIED SILICON DIOXIDE STARCH, CORN TALC TITANIUM DIOXIDE S;6;6 Bisoprolol fumarate Bisoprolol fumarate BISOPROLOL FUMARATE BISOPROLOL CROSPOVIDONE, UNSPECIFIED DIBASIC CALCIUM PHOSPHATE DIHYDRATE MAGNESIUM STEARATE MANNITOL MICROCRYSTALLINE CELLULOSE POLYETHYLENE GLYCOL, UNSPECIFIED POLYVINYL ALCOHOL, UNSPECIFIED SILICON DIOXIDE STARCH, CORN TALC TITANIUM DIOXIDE S;6;7"],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL 43547-616-03 Rx Only Bisoprolol Fumarate Tablets, USP 5 mg 30 Tablets Unit-of-use Each tablet contains 5 mg of bisoprolol Fumarate. Usual dosage : See package insert for complete prescribing information. Store at 20°C -25°C (68°F -77°F), excursions permitted to 15°C -30°C (59°F °-86°F). [See USP Controlled Room Temperature.] Protect from moisture. Dispense in tight, light resistant containers. Manufactured by: Prinston Laboratories Charlotte, NC 28206, USA Distributed by: Solco Healthcare US, LLC Somerset, NJ 08873, USA 9040561-01 Rev.: 06/2023 5","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL 43547-617-03 Rx Only Bisoprolol Fumarate Tablets, USP 10 mg 30 Tablets Unit-of-use Each tablet contains 10 mg of bisoprolol Fumarate. Usual dosage : See package insert for complete prescribing information. Store at 20°C -25°C (68°F -77°F), excursions permitted to 15°C °-30°C (59°F -86°F). [See USP Controlled Room Temperature.] Protect from moisture. Dispense in tight, light resistant containers. Manufactured by: Prinston Laboratories Charlotte, NC 28206, USA Distributed by: Solco Healthcare US, LLC Somerset, NJ 08873, USA 9040564-01 Rev.: 06/2023 10"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies were conducted with oral bisoprolol fumarate administered in the feed of mice (20 and 24 months) and rats (26 months). No evidence of carcinogenic potential was seen in mice dosed up to 250 mg/kg/day or rats dosed up to 125 mg/kg/day. On a body weight basis, these doses are 625 and 312 times, respectively, the maximum recommended human dose (MRHD) of 20 mg, (or 0.4 mg/kg/day based on a 50 kg individual); on a body surface area basis, these doses are 59 times (mice) and 64 times (rats) the MRHD. The mutagenic potential of bisoprolol fumarate was evaluated in the microbial mutagenicity (Ames) test, the point mutation and chromosome aberration assays in Chinese hamster V79 cells, the unscheduled DNA synthesis test, the micronucleus test in mice, and the cytogenetics assay in rats. There was no evidence of mutagenic potential in these in vitro and in vivo assays. Reproduction studies in rats did not show any impairment of fertility at doses up to 150 mg/kg/day of bisoprolol fumarate, or 375 and 77 times the MRHD on the basis of body weight and body surface area, respectively."]},"tags":[{"label":"beta-Adrenergic Blocker","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Beta-1 adrenergic receptor","category":"target"},{"label":"ADRB1","category":"gene"},{"label":"ADRB2","category":"gene"},{"label":"ADRB3","category":"gene"},{"label":"C07AB07","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Atrial fibrillation","category":"indication"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Teva Branded Pharm","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic beta-1 Receptor Antagonists","category":"pharmacology"},{"label":"Adrenergic beta-Antagonists","category":"pharmacology"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sympatholytics","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"8899 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"6855 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"6836 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"6321 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"6174 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"5983 reports"},{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"5616 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"5421 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"5266 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"5184 reports"}],"drugInteractions":[{"url":"/drug/chlorpropamide","drug":"chlorpropamide","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Chlorpropamide","source":"DrugCentral","drugSlug":"chlorpropamide"},{"url":"/drug/cimetidine","drug":"cimetidine","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Cimetidine","source":"DrugCentral","drugSlug":"cimetidine"},{"url":"/drug/disopyramide","drug":"disopyramide","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Disopyramide","source":"DrugCentral","drugSlug":"disopyramide"},{"url":"/drug/epinephrine","drug":"epinephrine","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Epinephrine","source":"DrugCentral","drugSlug":"epinephrine"},{"url":"/drug/felodipine","drug":"felodipine","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Felodipine","source":"DrugCentral","drugSlug":"felodipine"},{"url":"/drug/glibenclamide","drug":"glibenclamide","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Glyburide","source":"DrugCentral","drugSlug":"glibenclamide"},{"url":"/drug/glipizide","drug":"glipizide","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Glipizide","source":"DrugCentral","drugSlug":"glipizide"},{"url":"/drug/indomethacin","drug":"indomethacin","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Indomethacin","source":"DrugCentral","drugSlug":"indomethacin"},{"url":"/drug/piroxicam","drug":"piroxicam","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Piroxicam","source":"DrugCentral","drugSlug":"piroxicam"},{"url":"/drug/sulindac","drug":"sulindac","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Sulindac","source":"DrugCentral","drugSlug":"sulindac"},{"url":"/drug/tolazamide","drug":"tolazamide","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Tolazamide","source":"DrugCentral","drugSlug":"tolazamide"},{"url":"/drug/tolbutamide","drug":"tolbutamide","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate, Tolbutamide","source":"DrugCentral","drugSlug":"tolbutamide"},{"url":"/drug/verapamil","drug":"verapamil","action":"Avoid combination","effect":"May interact with Bisoprolol Fumarate, Verapamil","source":"DrugCentral","drugSlug":"verapamil"}],"commonSideEffects":[{"effect":"increased sweating","drugRate":"1.5%","_validated":true,"placeboRate":"0.7%"},{"effect":"arthralgia","drugRate":"2.3%","_validated":true,"placeboRate":"2.2%"},{"effect":"dizziness","drugRate":"3.8%","_validated":true,"placeboRate":"2.9%"},{"effect":"headache","drugRate":"11.4%","_validated":true,"placeboRate":"8.8%"},{"effect":"hypoaesthesia","drugRate":"0.8%","_validated":true,"placeboRate":"1.1%"},{"effect":"dry mouth","drugRate":"1.5%","_validated":true,"placeboRate":"0.7%"},{"effect":"bradycardia","drugRate":"0.4%","_validated":true,"placeboRate":"0.5%"},{"effect":"vivid dreams","drugRate":"0%","_validated":true,"placeboRate":"0%"},{"effect":"insomnia","drugRate":"2.3%","_validated":true,"placeboRate":"1.5%"},{"effect":"depression","drugRate":"0.8%","_validated":true,"placeboRate":"0%"},{"effect":"diarrhea","drugRate":"1.5%","_validated":true,"placeboRate":"2.6%"},{"effect":"nausea","drugRate":"1.5%","_validated":true,"placeboRate":"1.5%"},{"effect":"vomiting","drugRate":"0%","_validated":true,"placeboRate":"1.1%"},{"effect":"bronchospasm","drugRate":"0%","_validated":true,"placeboRate":"0%"},{"effect":"cough","drugRate":"4.5%","_validated":true,"placeboRate":"2.6%"},{"effect":"dyspnea","drugRate":"0.8%","_validated":true,"placeboRate":"1.1%"},{"effect":"pharyngitis","drugRate":"2.3%","_validated":true,"placeboRate":"2.2%"},{"effect":"rhinitis","drugRate":"3.0%","_validated":true,"placeboRate":"2.9%"},{"effect":"sinusitis","drugRate":"1.5%","_validated":true,"placeboRate":"2.2%"},{"effect":"URI","drugRate":"3.8%","_validated":true,"placeboRate":"4.8%"},{"effect":"asthenia","drugRate":"0%","_validated":true,"placeboRate":"0.4%"},{"effect":"chest pain","drugRate":"0.8%","_validated":true,"placeboRate":"1.1%"},{"effect":"fatigue","drugRate":"1.5%","_validated":true,"placeboRate":"6.6%"},{"effect":"edema (peripheral)","drugRate":"3.8%","_validated":true,"placeboRate":"3.7%"}],"contraindications":["Acute exacerbation of asthma","Acute pancreatitis","Anaphylaxis","Anuria","Asthma","Azotemia","Cardiogenic shock","Complete atrioventricular block","Decompensated cardiac failure","Dehydration","Depressive disorder","Diabetes mellitus","Disease of liver","Gout","Hepatic coma","Hypercalcemia","Hypercholesterolemia","Hyperparathyroidism","Hyperuricemia","Hypochloremic alkalosis","Hypokalemia","Hypomagnesemia","Hyponatremia","Hypovolemia","Kidney disease"],"specialPopulations":{"Pregnancy":"The bisoprolol fumarate/hydrochlorothiazide (B/H) combination was not teratogenic at doses up to 51.4 mg/kg/day of bisoprolol fumarate in combination with 128.6 mg/kg/day of hydrochlorothiazide.","Geriatric use":"In clinical trials, at least 270 patients treated with bisoprolol fumarate plus HCTZ were 60 years of age or older. HCTZ added significantly to the antihypertensive effect of bisoprolol in elderly hypertensive patients. No overall differences in effectiveness or safety were observed between these patients and younger patients.","Paediatric use":"Safety and effectiveness of bisoprolol fumarate and hydrochlorothiazide tablets in pediatric patients have not been established."},"discontinuationRates":[{"trial":"","drugArm":"3.3%","placeboArm":"6.8%","commonReason":"less than 1% for either bradycardia or fatigue/lack of energy"}]},"trials":[],"aliases":[],"company":"Teva","patents":[],"pricing":[],"_fixedAt":"2026-03-30T15:41:37.897019","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BISOPROLOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:21:06.292889+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Bisoprolol","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:21:15.326756+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:21:13.960553+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:21:04.919532+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BISOPROLOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:21:14.695725+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:03.768524+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:03.768567+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:21:16.293316+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL645/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:21:15.201368+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS Safety data are available in more than 30,000 patients or volunteers. Frequency estimates and rates of withdrawal of therapy for adverse events were derived from two U.S. placebo-controlled studies. In Study A, doses of 5, 10, and 20 mg bisoprolol fumarate were administered for 4 weeks. In Study B, doses of 2.5, 10, and 40 mg of bisoprolol fumarate were administered for 12 weeks. A total of 273 patients were treated with 5-20 mg of bisoprolol fumarate; 132 received placebo. Wit","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:57.716985+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA217368","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:03.768575+00:00"}},"allNames":"zebeta","offLabel":[],"synonyms":["bisoprolol hemifumarate","bisoprolol","bisoprolol fumarate"],"timeline":[{"date":"1992-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from TEVA WOMENS to Teva Branded Pharm"},{"date":"1992-07-31","type":"positive","source":"DrugCentral","milestone":"FDA approval (Teva Womens)"},{"date":"2013-06-28","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Toa Eiyo Ltd.)"},{"date":"2025-04-16","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 12 manufacturers approved"}],"aiSummary":"Zebeta (Bisoprolol) is a beta-adrenergic blocker, a small molecule that targets the beta-1 adrenergic receptor. It is used to treat atrial fibrillation and hypertensive disorders. Originally developed by TEVA WOMENS, it is now owned by Teva Branded Pharm and has been off-patent since its FDA approval in 1992. Zebeta is available as a generic medication from multiple manufacturers. As a beta-blocker, it is essential to monitor patients for signs of bradycardia, hypotension, and worsening heart failure.","brandName":"Zebeta","ecosystem":[{"indication":"Atrial fibrillation","otherDrugs":[{"name":"acetyldigitoxin","slug":"acetyldigitoxin","company":"Novartis"},{"name":"clopidogrel","slug":"clopidogrel","company":"Sanofi Aventis Us"},{"name":"digoxin","slug":"digoxin","company":"Eurohlth Intl Sarl"},{"name":"diltiazem","slug":"diltiazem","company":"Valeant Intl"}],"globalPrevalence":59000000},{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Beta-1 adrenergic receptor","novelty":"Follow-on","targets":[{"gene":"ADRB1","source":"DrugCentral","target":"Beta-1 adrenergic receptor","protein":"Beta-1 adrenergic receptor","isPrimary":true,"activityType":"Ki","activityValue":7.65},{"gene":"ADRB2","source":"DrugCentral","target":"Beta-2 adrenergic receptor","protein":"Beta-2 adrenergic receptor"},{"gene":"ADRB3","source":"DrugCentral","target":"Beta-3 adrenergic receptor","protein":"Beta-3 adrenergic receptor"}],"moaClass":"Adrenergic beta-Antagonists","modality":"Small Molecule","drugClass":"beta-Adrenergic Blocker","explanation":"","oneSentence":"","technicalDetail":"Bisoprolol selectively binds to the beta-1 adrenergic receptor, inhibiting the effects of endogenous catecholamines, such as epinephrine and norepinephrine, which leads to decreased heart rate, contractility, and cardiac output, ultimately resulting in reduced blood pressure and alleviated symptoms of atrial fibrillation and hypertensive disorders."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Bisoprolol","title":"Bisoprolol","extract":"Bisoprolol, sold under the brand names Bisotab, Concor, Corbis and Zebeta among others, is a beta blocker which is selective for the beta-1 receptor and used for cardiovascular diseases, including tachyarrhythmias, high blood pressure, angina, and heart failure. It is taken by mouth."},"commercial":{"launchDate":"1992","_launchSource":"DrugCentral (FDA 1992-07-31, TEVA WOMENS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/380","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BISOPROLOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BISOPROLOL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Bisoprolol","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:04:19.399896","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:21:59.587425+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"metoprolol","drugSlug":"metoprolol","fdaApproval":"1978-08-07","patentExpiry":"Jul 9, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"atenolol","drugSlug":"atenolol","fdaApproval":"1981-08-19","genericCount":22,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acebutolol","drugSlug":"acebutolol","fdaApproval":"1984-12-28","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"betaxolol","drugSlug":"betaxolol","fdaApproval":"1985-08-30","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"esmolol","drugSlug":"esmolol","fdaApproval":"1986-12-31","patentExpiry":"Mar 15, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nebivolol","drugSlug":"nebivolol","fdaApproval":"2007-12-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"bisoprolol","indications":{"approved":[{"name":"Atrial fibrillation","source":"DrugCentral","snomedId":49436004,"regulator":"FDA","eligibility":"No eligibility criteria mentioned","usPrevalence":6100000,"globalPrevalence":59000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet, 2023"},{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA","eligibility":"No eligibility criteria mentioned"}],"offLabel":[{"name":"Angina pectoris","source":"DrugCentral","drugName":"BISOPROLOL","evidenceCount":90,"evidenceLevel":"strong"},{"name":"Chronic heart failure","source":"DrugCentral","drugName":"BISOPROLOL","evidenceCount":293,"evidenceLevel":"strong"},{"name":"Diastolic heart failure","source":"DrugCentral","drugName":"BISOPROLOL","evidenceCount":68,"evidenceLevel":"strong"},{"name":"Prevention of Post Cardio-Thoracic Surgery Atrial Fibrillation","source":"DrugCentral","drugName":"BISOPROLOL","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"_fixedFields":["primaryTarget"],"currentOwner":"Teva Branded Pharm","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"metoprolol","brandName":"metoprolol","genericName":"metoprolol","approvalYear":"1978","relationship":"same-class"},{"drugId":"atenolol","brandName":"atenolol","genericName":"atenolol","approvalYear":"1981","relationship":"same-class"},{"drugId":"acebutolol","brandName":"acebutolol","genericName":"acebutolol","approvalYear":"1984","relationship":"same-class"},{"drugId":"betaxolol","brandName":"betaxolol","genericName":"betaxolol","approvalYear":"1985","relationship":"same-class"},{"drugId":"esmolol","brandName":"esmolol","genericName":"esmolol","approvalYear":"1986","relationship":"same-class"},{"drugId":"nebivolol","brandName":"nebivolol","genericName":"nebivolol","approvalYear":"2007","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07045038","phase":"NA","title":"Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2025-01-20","conditions":["Heart Failure NYHA Class II"],"enrollment":60,"completionDate":"2026-04"},{"nctId":"NCT07491718","phase":"NA","title":"Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-08-08","conditions":["Takotsubo Cardiomyopathy"],"enrollment":100,"completionDate":"2028-08-09"},{"nctId":"NCT07445334","phase":"NA","title":"Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes","status":"NOT_YET_RECRUITING","sponsor":"Western Sydney Local Health District","startDate":"2026-03-01","conditions":["Premature Ventricular Complexes","Premature Ventricular Contraction (PVC)","Premature Ventricular Beats"],"enrollment":40,"completionDate":"2028-03-01"},{"nctId":"NCT07298993","phase":"PHASE4","title":"Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)","status":"ENROLLING_BY_INVITATION","sponsor":"Weill Medical College of Cornell University","startDate":"2026-02-02","conditions":["Heart Failure","HFpEF","HFpEF - Heart Failure With Preserved Ejection Fraction"],"enrollment":240,"completionDate":"2029-04"},{"nctId":"NCT07405229","phase":"PHASE4","title":"MEdical Treatment in Idiopathic Ventricular Fibrillation Patients","status":"RECRUITING","sponsor":"Bo Gregers Winkel","startDate":"2018-05-01","conditions":["Idiopathic Ventricular Fibrillation","Cardiac Arrest, Out-Of-Hospital"],"enrollment":218,"completionDate":"2035-12-31"},{"nctId":"NCT07103655","phase":"PHASE4","title":"The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":["Hypertrophic Cardiomyopathy (HCM)"],"enrollment":132,"completionDate":"2027-01-01"},{"nctId":"NCT06518694","phase":"PHASE3","title":"Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-02-11","conditions":["Heart Failure"],"enrollment":1300,"completionDate":"2027-10"},{"nctId":"NCT04513509","phase":"NA","title":"Rate Control in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2020-10-21","conditions":["Atrial Fibrillation","Rate Control","Cardiopulmonary Exercise Test"],"enrollment":13,"completionDate":"2022-07-01"},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":["Severe Aortic Valve Stenosis"],"enrollment":25,"completionDate":"2027-05-30"},{"nctId":"NCT07327749","phase":"PHASE4","title":"Comparing Bisoprolol and Valsartan-Amlodipine for Hypertension","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2022-10-01","conditions":["Hypertension"],"enrollment":59,"completionDate":"2025-12-12"},{"nctId":"NCT07238452","phase":"PHASE4","title":"Optimising Pacing Therapy, Integrated Medical Therapy, and Catheter AbLation for Atrial Fibrillation in Heart Failure Trial","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-12-01","conditions":["Heart Failure With Reduced Ejection Fraction","Atrial Fibrillation (AF)"],"enrollment":1056,"completionDate":"2033-01-01"},{"nctId":"NCT05794997","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-30","conditions":["Hypertension"],"enrollment":817337,"completionDate":"2023-12-31"},{"nctId":"NCT05019027","phase":"PHASE4","title":"N-of-1 for Beta-Blockers in Cardiac Amyloidosis","status":"ENROLLING_BY_INVITATION","sponsor":"Weill Medical College of Cornell University","startDate":"2024-01-31","conditions":["Cardiac Amyloidosis","Heart Diseases","TTR Cardiac Amyloidosis"],"enrollment":20,"completionDate":"2026-12-31"},{"nctId":"NCT05585125","phase":"PHASE4","title":"A Preliminary Study for INFORMED","status":"ENROLLING_BY_INVITATION","sponsor":"Weill Medical College of Cornell University","startDate":"2024-02-07","conditions":["Heart Failure","Heart Failure, Diastolic","Heart Failure With Preserved Ejection Fraction","Cardiac Failure","Heart Diseases"],"enrollment":20,"completionDate":"2026-07"},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":["Chronic Heart Failure","Chronic Heart Failure With Reduced Ejection Fraction"],"enrollment":4936,"completionDate":"2025-09-19"},{"nctId":"NCT07123506","phase":"NA","title":"Beta-blockers for Prevention of Supraventricular Arrhythmia Following PFO Closure","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-09","conditions":["Atrial Fibrillation","Atrial Flutter","Tachycardia, Supraventricular","Heart Septal Defects, Atrial"],"enrollment":350,"completionDate":"2029-05-03"},{"nctId":"NCT06562582","phase":"PHASE4","title":"STunning in Acute Myocardial Infarction - BAS","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-01-06","conditions":["Myocardial Infarct"],"enrollment":120,"completionDate":"2027-12-31"},{"nctId":"NCT06930092","phase":"NA","title":"RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-07-01","conditions":["Ischemic Cardiomyopathy"],"enrollment":158,"completionDate":"2029-04-30"},{"nctId":"NCT07029906","phase":"NA","title":"pErsonalised Nocebo Assessment of Beta-blockEr Symptoms in Heart Failure","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2025-04-29","conditions":["Side-Effect","Heart Failure"],"enrollment":150,"completionDate":"2027-12"},{"nctId":"NCT03778554","phase":"PHASE4","title":"Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bispebjerg Hospital","startDate":"2018-12-17","conditions":["Acute Myocardial Infarction","Non-ST Elevation Myocardial Infarction (nSTEMI)","ST Elevation Myocardial Infarction"],"enrollment":2760,"completionDate":"2035-12-10"},{"nctId":"NCT06453577","phase":"","title":"Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2023-05-01","conditions":["Acute Decompensated Heart Failure"],"enrollment":12,"completionDate":"2025-12-31"},{"nctId":"NCT03646357","phase":"PHASE4","title":"BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2018-10-01","conditions":["Acute Myocardial Infarction","Non-ST Elevation Myocardial Infarction","ST Elevation Myocardial Infarction"],"enrollment":2895,"completionDate":"2035-12-10"},{"nctId":"NCT03596385","phase":"PHASE4","title":"TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion\"","status":"COMPLETED","sponsor":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","startDate":"2018-10-31","conditions":["Myocardial Infarction"],"enrollment":8505,"completionDate":"2025-01-31"},{"nctId":"NCT05288400","phase":"PHASE3","title":"Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.","status":"COMPLETED","sponsor":"Servier","startDate":"2018-05-14","conditions":["Essential Hypertension"],"enrollment":150,"completionDate":"2018-12-18"},{"nctId":"NCT06699342","phase":"NA","title":"Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-01-27","conditions":["Atrial Fibrillation (AF)"],"enrollment":50,"completionDate":"2027-12-31"},{"nctId":"NCT03917914","phase":"PHASE3","title":"Preventing Adverse Cardiac Events in COPD","status":"COMPLETED","sponsor":"The George Institute","startDate":"2020-06-30","conditions":["Chronic Obstructive Pulmonary Disease","Cardiovascular Diseases"],"enrollment":280,"completionDate":"2025-03-31"},{"nctId":"NCT06831864","phase":"PHASE1","title":"Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2025-02-15","conditions":["Heart Failure With Reduced Ejection Fraction"],"enrollment":40,"completionDate":"2025-05-05"},{"nctId":"NCT05637853","phase":"PHASE4","title":"Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-10-22","conditions":["Heart Failure With Reduced Ejection Fraction"],"enrollment":60,"completionDate":"2026-08-26"},{"nctId":"NCT05569382","phase":"PHASE4","title":"Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy","status":"RECRUITING","sponsor":"Morten Steen Kvistholm Jensen","startDate":"2022-08-10","conditions":["Non-obstructive Hypertrophic Cardiomyopathy"],"enrollment":100,"completionDate":"2027-12-31"},{"nctId":"NCT06276127","phase":"PHASE3","title":"Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate.","status":"NOT_YET_RECRUITING","sponsor":"Oman Medical Speciality Board","startDate":"2025-04","conditions":["Atrial Fibrillation With Rapid Ventricular Response","Atrial Flutter With Rapid Ventricular Response"],"enrollment":60,"completionDate":"2027-06"},{"nctId":"NCT03640312","phase":"PHASE2","title":"Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-08-30","conditions":["Hypertension"],"enrollment":62,"completionDate":"2024-07-31"},{"nctId":"NCT04823442","phase":"NA","title":"Activation of Brown Adipose Tissue Metabolism Using Mirabegron","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2021-01-21","conditions":["Type 2 Diabetes"],"enrollment":9,"completionDate":"2022-04-04"},{"nctId":"NCT04656847","phase":"","title":"PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2021-03-01","conditions":["Coronary Artery Disease","Myocardial Infarction","Arterial Hypertension"],"enrollment":504,"completionDate":"2021-10-18"},{"nctId":"NCT06657404","phase":"NA","title":"The Modified \"Pills-in-the-Pocket\" Strategy","status":"RECRUITING","sponsor":"Yumei Xue","startDate":"2024-10-23","conditions":["Atrial Fibrillation (AF)"],"enrollment":328,"completionDate":"2024-12-31"},{"nctId":"NCT06643221","phase":"EARLY_PHASE1","title":"Exercise as an Immune Adjuvant for Allogeneic Cell Therapies","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2018-01-24","conditions":["Leukemia","Hematopoetic Stem Cell Transplantation","Donor Lymphocyte Infusion","CAR T-Cell Therapy","Lymphoma","Cell Therapy"],"enrollment":100,"completionDate":"2028-12-30"},{"nctId":"NCT05880056","phase":"PHASE4","title":"Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension","status":"RECRUITING","sponsor":"Genuine Research Center, Egypt","startDate":"2024-08-08","conditions":["Essential Hypertension"],"enrollment":406,"completionDate":"2025-04-01"},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":["Myocardial Infarction With Non-Obstructive Coronary Arteries"],"enrollment":120,"completionDate":"2025-07"},{"nctId":"NCT04757584","phase":"PHASE4","title":"Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-04-01","conditions":["Heart Failure","Heart Failure, Diastolic","Heart Failure With Preserved Ejection Fraction","Cardiac Failure","Heart Disease"],"enrollment":9,"completionDate":"2023-04-28"},{"nctId":"NCT03278509","phase":"PHASE4","title":"Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska Institutet","startDate":"2017-09-11","conditions":["Acute Myocardial Infarction","Non-ST Elevation Myocardial Infarction","ST Elevation Myocardial Infarction"],"enrollment":5000,"completionDate":"2025-12-31"},{"nctId":"NCT06035978","phase":"PHASE4","title":"Determination of Drug Levels for Pharmacotherapy of Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Ostrava","startDate":"2024-03","conditions":["Cardiovascular Diseases","Heart Failure With Reduced Ejection Fraction"],"enrollment":100,"completionDate":"2026-04"},{"nctId":"NCT04767061","phase":"PHASE4","title":"Impact of Beta-blockers on Physical Function in HFpEF","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-04-01","conditions":["Heart Failure","Heart Failure, Diastolic","Heart Failure With Preserved Ejection Fraction","Cardiac Failure","Heart Disease"],"enrollment":9,"completionDate":"2023-04-28"},{"nctId":"NCT05930808","phase":"PHASE1","title":"Concor® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2023-02-28","conditions":["Healthy"],"enrollment":46,"completionDate":"2023-06-18"},{"nctId":"NCT05730413","phase":"PHASE4","title":"Once Versus Twice Bisoprolol Dosage Regimen in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft Surgery","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2021-08-25","conditions":["Coronary Artery Bypass Grafting","Postoperative Atrial Fibrillation","Coronary Artery Disease"],"enrollment":122,"completionDate":"2023-09"},{"nctId":"NCT02364089","phase":"NA","title":"Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2015-04-09","conditions":["Adrenal Incidentalomas"],"enrollment":78,"completionDate":"2022-11-23"},{"nctId":"NCT05536284","phase":"PHASE2","title":"Potential Drug Interactions With Bisoprolol in Egyptian Patients With ACS","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2021-09-01","conditions":["Acute Coronary Syndrome"],"enrollment":128,"completionDate":"2022-08-16"},{"nctId":"NCT05536271","phase":"PHASE2","title":"Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2021-09-01","conditions":["Acute Coronary Syndrome"],"enrollment":127,"completionDate":"2022-08-16"},{"nctId":"NCT02817360","phase":"PHASE4","title":"NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients","status":"RECRUITING","sponsor":"Martin Huelsmann","startDate":"2016-02","conditions":["Heart Diseases","Diabetes Mellitus, Type 2"],"enrollment":2400,"completionDate":"2026-12"},{"nctId":"NCT04588935","phase":"PHASE2","title":"Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer","status":"COMPLETED","sponsor":"State Institution \"Republican Scientific and Practical Center\" Cardiology, Belarus","startDate":"2019-07-01","conditions":["Women With Breast Cancer"],"enrollment":100,"completionDate":"2023-02-07"},{"nctId":"NCT04432610","phase":"PHASE4","title":"Echocardiographic Study of a Single Dose Bisoprolol Versus Nebivolol in Healthy Subjects","status":"WITHDRAWN","sponsor":"Clinical Hospital Center Zemun","startDate":"2030-01","conditions":["Bisoprolol Adverse Reaction","Nebivolol Adverse Reaction"],"enrollment":0,"completionDate":"2030-12"},{"nctId":"NCT05430048","phase":"PHASE2","title":"Nasal Desmopressin Versus Oral Bisoprolol for Controlling Bleeding During Endoscopic Sinus Surgery","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2022-07-01","conditions":["Bleeding"],"enrollment":100,"completionDate":"2022-11-05"},{"nctId":"NCT05580510","phase":"PHASE2,PHASE3","title":"\" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD \"","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2023-02-06","conditions":["Congenital Heart Disease","Heart Failure","Heart Failure With Reduced Ejection Fraction"],"enrollment":160,"completionDate":"2024-03-29"},{"nctId":"NCT04555109","phase":"","title":"Convalescent Plasma for COVID-19 Research Donor Study","status":"UNKNOWN","sponsor":"The Hospital for Sick Children","startDate":"2020-06-30","conditions":["Covid19"],"enrollment":1000,"completionDate":"2022-10-31"},{"nctId":"NCT03779646","phase":"PHASE2,PHASE3","title":"Bisoprolol in DMD Early Cardiomyopathy","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-01-16","conditions":["Duchenne Muscular Dystrophy","Cardiomyopathy, Dilated"],"enrollment":42,"completionDate":"2024-07-01"},{"nctId":"NCT05540600","phase":"PHASE3","title":"Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: Digoxin Versus Beta Blocker","status":"UNKNOWN","sponsor":"University of Monastir","startDate":"2022-09-12","conditions":["Atrial Fibrillation","Left Atrial Rhythm"],"enrollment":30,"completionDate":"2023-12-01"},{"nctId":"NCT05294887","phase":"PHASE4","title":"Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2022-03-04","conditions":["Coronary Microvascular Dysfunction","Microvascular Angina","Vasospasm, Coronary","Vasospastic Angina","Prinzmetal Angina","Coronary Artery Disease"],"enrollment":132,"completionDate":"2024-06"},{"nctId":"NCT04542785","phase":"NA","title":"Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Danish Atrial Fibrillation Randomised Clinical Trial","status":"UNKNOWN","sponsor":"Holbaek Sygehus","startDate":"2021-03-31","conditions":["Atrial Fibrillation, Persistent","Atrial Fibrillation Chronic","Atrial Fibrillation"],"enrollment":350,"completionDate":"2026-03-02"},{"nctId":"NCT03011775","phase":"PHASE4","title":"Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2012-11","conditions":["Adverse Effect","Atherosclerosis, Coronary","Insulin Resistance Syndrome"],"enrollment":43,"completionDate":"2015-09"},{"nctId":"NCT02236806","phase":"PHASE3","title":"Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2015-07","conditions":["Breast Cancer","Cardiotoxicity"],"enrollment":262,"completionDate":"2022-06"},{"nctId":"NCT05175066","phase":"PHASE3","title":"Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-11-12","conditions":["Cardiomyopathies","Chemotherapy Effect","Diastolic Dysfunction","Systolic Dysfunction"],"enrollment":80,"completionDate":"2021-12-02"},{"nctId":"NCT04356196","phase":"EARLY_PHASE1","title":"Comparative Study Between the Efficacy of Verapamil and Bisoprolol on Reduction of Bleeding During Endoscopic Sinus Surgery Under General Anaesthesia.","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-06-15","conditions":["Endoscopic Sinus Surgery","Heart Rate","Blood Loss"],"enrollment":135,"completionDate":"2021-12-30"},{"nctId":"NCT04320589","phase":"PHASE2","title":"the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2019-06-30","conditions":["Pheochromocytoma"],"enrollment":30,"completionDate":"2021-08-30"},{"nctId":"NCT02355821","phase":"NA","title":"Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women","status":"COMPLETED","sponsor":"National Research Center for Preventive Medicine","startDate":"2015-04","conditions":["Osteopenia","Arterial Hypertension"],"enrollment":114,"completionDate":"2018-07-10"},{"nctId":"NCT01742702","phase":"","title":"HaemoDYNAMICs in Primary and Secondary Hypertension","status":"UNKNOWN","sponsor":"Tampere University","startDate":"2006-05-25","conditions":["Primary Hypertension","Secondary Hypertension","Aortic Stenosis","Renal Insufficiency"],"enrollment":2000,"completionDate":"2025-12-31"},{"nctId":"NCT04991896","phase":"","title":"Beta Blockers Plus Intravenous Flecainide for Paroxysmal Atrial Fibrillation: a Real-world Chios Registry (BETAFLEC-CHIOS)","status":"COMPLETED","sponsor":"AHEPA University Hospital","startDate":"2020-01-01","conditions":["Atrial Fibrillation","Arrhythmias, Cardiac"],"enrollment":81,"completionDate":"2021-06-30"},{"nctId":"NCT04575675","phase":"PHASE4","title":"Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy","status":"COMPLETED","sponsor":"Cheng-Hsin General Hospital","startDate":"2020-05-29","conditions":["Hypotension","Heart Failure"],"enrollment":78,"completionDate":"2020-12-30"},{"nctId":"NCT02391337","phase":"PHASE4","title":"Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)","status":"COMPLETED","sponsor":"University of Birmingham","startDate":"2016-12-20","conditions":["Permanent Atrial Fibrillation"],"enrollment":161,"completionDate":"2019-09-16"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT04085562","phase":"PHASE4","title":"Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2019-09-01","conditions":["Hypertension, Renal"],"enrollment":46,"completionDate":"2021-02-01"},{"nctId":"NCT02086019","phase":"NA","title":"Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes","status":"COMPLETED","sponsor":"Brighton and Sussex University Hospitals NHS Trust","startDate":"2014-05-01","conditions":["Acute Coronary Syndromes"],"enrollment":250,"completionDate":"2019-12-12"},{"nctId":"NCT03730116","phase":"","title":"Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2018-11-14","conditions":["Arterial Hypertension","CHD - Coronary Heart Disease"],"enrollment":1909,"completionDate":"2019-10-24"},{"nctId":"NCT04704947","phase":"PHASE3","title":"Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2017-10-01","conditions":["Beta Blocker Toxicity"],"enrollment":50,"completionDate":"2030-10-01"},{"nctId":"NCT02398929","phase":"PHASE4","title":"BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2013-01","conditions":["Hypertension"],"enrollment":100,"completionDate":"2021-01-05"},{"nctId":"NCT04484688","phase":"","title":"Prestilol(Perindopril+Bisoprolol) in Therapy of Patients With Atrial Fibrilation","status":"UNKNOWN","sponsor":"Aversi Clinic","startDate":"2020-08-01","conditions":["Patient Participation"],"enrollment":50,"completionDate":"2021-12-01"},{"nctId":"NCT01868880","phase":"PHASE4","title":"Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing","status":"WITHDRAWN","sponsor":"Policlinico Casilino ASL RMB","startDate":"2016-02","conditions":["Heart Rate Control in ICD Patients With Heart Failure"],"enrollment":0,"completionDate":"2023-12"},{"nctId":"NCT03850093","phase":"PHASE4","title":"Preoperative Gabapentin Versus Bisoprolol for Hemodynamic Optimization During Sinus Surgery","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2015-08","conditions":["Blood Pressure"],"enrollment":63,"completionDate":"2016-12"},{"nctId":"NCT03026088","phase":"PHASE4","title":"Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2017-03-21","conditions":["Heart Failure"],"enrollment":20,"completionDate":"2018-12-26"},{"nctId":"NCT02598505","phase":"PHASE3","title":"Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation","status":"COMPLETED","sponsor":"Centro Cardiologico Monzino","startDate":"2015-09","conditions":["Heart Failure"],"enrollment":44,"completionDate":"2016-11"},{"nctId":"NCT04223739","phase":"PHASE4","title":"Comparison of Two Strategies for the Management of Atrial Fibrillation After Cardiac Surgery","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2019-12-13","conditions":["Atrial Fibrillation","Cardiac Surgery"],"enrollment":380,"completionDate":"2022-06-01"},{"nctId":"NCT04221919","phase":"NA","title":"Different β -Blockers in STEMI and Primary PCI","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2020-01","conditions":["Primary PCI"],"enrollment":1200,"completionDate":"2025-01"},{"nctId":"NCT02200822","phase":"PHASE4","title":"Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2014-07","conditions":["Heart Failure (HF)"],"enrollment":80,"completionDate":"2019-02"},{"nctId":"NCT02380053","phase":"PHASE4","title":"Chronic Beta-blockade and Cardiopulmonary Exercise in COPD","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2016-06-07","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":10,"completionDate":"2019-04-30"},{"nctId":"NCT03967496","phase":"","title":"Assessment of Immediate Postoperative Delirium (IPD) in Adult Patients: Incidence and Etiologic Factors","status":"COMPLETED","sponsor":"Sultan Qaboos University","startDate":"2019-01-01","conditions":["Delirium","Anesthesia; Adverse Effect"],"enrollment":402,"completionDate":"2019-03-31"},{"nctId":"NCT01656005","phase":"PHASE4","title":"Beta Blocker Therapy in Moderate to Severe COPD","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2012-08","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":18,"completionDate":"2016-07"},{"nctId":"NCT02832973","phase":"PHASE4","title":"Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension","status":"COMPLETED","sponsor":"Sao Jose do Rio Preto Medical School","startDate":"2015-09","conditions":["Hypertension Resistant to Conventional Therapy"],"enrollment":72,"completionDate":"2018-03"},{"nctId":"NCT03226275","phase":"PHASE1","title":"Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2017-08-09","conditions":["Healthy"],"enrollment":32,"completionDate":"2017-09-09"},{"nctId":"NCT03800264","phase":"PHASE4","title":"Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-05-02","conditions":["Prevention","Atrial Fibrillation","CABG"],"enrollment":176,"completionDate":"2018-11-15"},{"nctId":"NCT03701880","phase":"NA","title":"Early Use of Ivabradine in Heart Failure","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2018-09-16","conditions":["Heart Failure With Reduced Ejection Fraction","Decompensated Heart Failure"],"enrollment":50,"completionDate":"2019-12-23"},{"nctId":"NCT03644446","phase":"","title":"Bisoprolol Plasma Residual Concentrations in Chronic Heart Failure","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2017-11-02","conditions":["Heart Failure With Reduced Ejection Fraction"],"enrollment":81,"completionDate":"2020-11-02"},{"nctId":"NCT02507050","phase":"PHASE4","title":"Ivabradine and Post-revascularisation Microcirculatory Dysfunction","status":"WITHDRAWN","sponsor":"Liverpool Heart and Chest Hospital NHS Foundation Trust","startDate":"2016-03","conditions":["Coronary Artery Disease","Angina"],"enrollment":0,"completionDate":"2016-03"},{"nctId":"NCT01579058","phase":"PHASE4","title":"Effect of Bisoprolol on Progression of Aortic Stenosis","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2012-07","conditions":["Aortic Stenosis"],"enrollment":20,"completionDate":"2014-05"},{"nctId":"NCT02171988","phase":"PHASE4","title":"Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-03","conditions":["Postural Orthostatic Tachycardia Syndrome"],"enrollment":150,"completionDate":"2016-12"},{"nctId":"NCT03485482","phase":"PHASE3","title":"Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-03-01","conditions":["Cardiovascular Diseases"],"enrollment":18,"completionDate":"2018-03-23"},{"nctId":"NCT02764970","phase":"","title":"Heart Rate Reducing Therapy in Cardiac CT Using Ivabradine and Bisoprolol","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2015-02","conditions":["Bradycardia"],"enrollment":112,"completionDate":"2016-01"},{"nctId":"NCT02539810","phase":"PHASE4","title":"Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09","conditions":["Hypertension","Hypertension Resistant to Conventional Therapy","Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent"],"enrollment":4,"completionDate":"2017-07"},{"nctId":"NCT03361280","phase":"PHASE1,PHASE2","title":"Removal of Beta Blocker Drugs by Hemodialysis","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2015-02-27","conditions":["Chronic Kidney Diseases"],"enrollment":8,"completionDate":"2016-03-10"},{"nctId":"NCT03276598","phase":"PHASE4","title":"A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"1999-11-25","conditions":["Hypertension","Pharmacogenetics"],"enrollment":233,"completionDate":"2004-04-01"},{"nctId":"NCT02599857","phase":"NA","title":"The Effects of a CONCOR Smartphone Application","status":"WITHDRAWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2017-01-01","conditions":["Congenital Heart Disease","Smartphone Application","Arrhythmia","Heart Failure","mHealth","Mobile Health"],"enrollment":0,"completionDate":"2017-05-01"},{"nctId":"NCT01251146","phase":"PHASE4","title":"A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2010-11","conditions":["Hypertension"],"enrollment":177,"completionDate":"2012-02"},{"nctId":"NCT01190436","phase":"PHASE4","title":"A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Filipino Hypertensive Subjects With Diabetes","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-12","conditions":["Hypertension"],"enrollment":125,"completionDate":"2011-12"},{"nctId":"NCT01977794","phase":"PHASE3","title":"Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-03","conditions":["Hypertension"],"enrollment":200,"completionDate":"2015-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"BISOPROLOL FUMARATE"},{"form":"TABLET","route":"ORAL","productName":"Bisoprolol Fumarate"},{"form":"TABLET","route":"ORAL","productName":"Bisoprolol Fumarate and Hydrochlorothiazide"},{"form":"TABLET","route":"ORAL","productName":"Bisoprolol fumarate"},{"form":"TABLET","route":"ORAL","productName":"bisoprolol fumarate and hydrochlorothiazide"},{"form":"TABLET, COATED","route":"ORAL","productName":"Bisoprolol Fumarate and Hydrochlorothiazide"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"BISOPROLOL FUMARATE"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Bisoprolol"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Bisoprolol Fumarate"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Bisoprolol Fumarate and Hydrochlorothiazide"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Ziac"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"bisoprolol fumarate and hydrochlorothiazide"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000021928","MMSL":"38369","NDDF":"003703","UNII":"Y41JS2NL6U","VUID":"4023923","CHEBI":"CHEBI:3127","VANDF":"4020862","INN_ID":"5225","RXNORM":"142146","UMLSCUI":"C0053799","chemblId":"CHEMBL645","ChEMBL_ID":"CHEMBL645","KEGG_DRUG":"D00634","DRUGBANK_ID":"DB00612","PUBCHEM_CID":"2405","SNOMEDCT_US":"108547003","IUPHAR_LIGAND_ID":"7129","SECONDARY_CAS_RN":"104344-23-2","MESH_DESCRIPTOR_UI":"D017298"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"Teva Womens Health, Inc.","brandName":"Ziac","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1992-","companyName":"Teva Womens","relationship":"Original Developer"},{"period":"present","companyName":"Teva Branded Pharm","relationship":"Current Owner"},{"period":"2013","companyName":"Toa Eiyo Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"10.0 hours","clearance":"3.7 mL/min/kg","bioavailability":"90%","fractionUnbound":"0.66%","volumeOfDistribution":"2.4 L/kg"},"publicationCount":2032,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C07AB07","allCodes":["C07AB07","C07BB07","C07FB07","C07FX04","C09BX02","C09BX04","C09BX05"]},"biosimilarFilings":[],"originalDeveloper":"Teva Womens","recentPublications":[{"date":"2026 Mar","pmid":"41877729","title":"One- and two-year structural changes of mavacamten therapy in hypertrophic obstructive cardiomyopathy: a case report with serial comprehensive CMR demonstrating continuous reverse remodelling.","journal":"European heart journal. Case reports"},{"date":"2026 Mar 11","pmid":"41810798","title":"Systemic medications associate with surgically treated cataract among adults over 50 years in Finland.","journal":"Acta ophthalmologica"},{"date":"2026 Mar","pmid":"41809863","title":"Acute effects of low-dose bisoprolol on lung function and blood pressure in COPD patients.","journal":"ERJ open research"},{"date":"2026 Mar 11","pmid":"41808274","title":"Unrepaired Truncus Arteriosus Type 1 With Eisenmenger Syndrome and Recurrent Embolic Strokes: An Adult Case Report.","journal":"The American journal of case reports"},{"date":"2026 Feb","pmid":"41804409","title":"A Prospective Clinical Audit to Improve Compliance With Perioperative Atrial Fibrillation Prevention Protocols in Off-Pump Coronary Artery Bypass Surgery.","journal":"Cureus"}],"companionDiagnostics":[],"genericManufacturers":13,"_genericFilersChecked":true,"genericManufacturerList":["Alembic","Aurobindo Pharma","Dash Pharms Natco","Harman Finochem","Micro Labs","Novitium Pharma","Prinston Inc","Rubicon Research","Teva Pharms","Tp Anda Holdings","Unichem","Unique Pharm","Zydus Lifesciences"],"status":"approved","companyName":"Teva Branded Pharm","companyId":"teva","modality":"Small molecule","firstApprovalDate":"1992","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-10-25T00:00:00.000Z","mah":"TP ANDA HOLDINGS","brand_name_local":null,"application_number":"ANDA075474"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-01-11T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":null,"application_number":"ANDA204891"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-01-18T00:00:00.000Z","mah":"HARMAN FINOCHEM","brand_name_local":null,"application_number":"ANDA217617"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-06-25T00:00:00.000Z","mah":"MYLAN","brand_name_local":null,"application_number":"ANDA075768"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-04-16T00:00:00.000Z","mah":"UNIQUE PHARM","brand_name_local":null,"application_number":"ANDA219044"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:21:59.587425+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}